Wegovy and Ozempic maker forecasts sharp drop in revenue for 2026
- Thread starter DreamEcho
- Start date
the whole thing just highlights how messed up the system is 
omg can u believe novo nordisk is expecting a 13% slump in sales ?? like what's going on?? they must have been doing something right before trump came along and started messing with their pricing 
i mean i get it, people need affordable meds but not at the cost of losing money for these companies 
anyway, it'll be interesting to see how eli lilly's mounjaro performs... maybe its time for novo nordisk to rethink their strategy 
i mean i get it, people need affordable meds but not at the cost of losing money for these companies anyway, it'll be interesting to see how eli lilly's mounjaro performs... maybe its time for novo nordisk to rethink their strategy I feel bad for Novo Nordisk 
. They're basically losing out on a fortune because of President Trump's weight loss drug price push. I get that it was trying to make meds more affordable, but geez, did they have to take such a huge hit? It's like they're playing a game of musical chairs, except instead of chairs, it's their revenue 
. Meanwhile, Eli Lilly is over here killing it with Mounjaro 
and GSK is being all cautious about its own price cuts 
. I just wish Novo Nordisk would stay positive and keep on truckin' 
- they're gonna need to be resilient for the future 
. They're basically losing out on a fortune because of President Trump's weight loss drug price push. I get that it was trying to make meds more affordable, but geez, did they have to take such a huge hit? It's like they're playing a game of musical chairs, except instead of chairs, it's their revenue . Meanwhile, Eli Lilly is over here killing it with Mounjaro and GSK is being all cautious about its own price cuts . I just wish Novo Nordisk would stay positive and keep on truckin' - they're gonna need to be resilient for the future 
i'm not surprised tho 
novo nordisk is already a massive company and they can absorb some financial hit... but 13% slump? that's steep! 
what if other big pharma companies follow suit? it'll be a domino effect 
. mounjaro by eli lilly seems like a good bet, but we all know those clinical trials are just as fake as the ones for most meds... 
anyway, hope mike doustdar knows what he's talking about 
This news highlights a paradoxical dynamic where the reduced prices for weight loss medications, intended to benefit consumers, have had a profoundly adverse effect on pharmaceutical companies' financials. Novo Nordisk's anticipated 13% sales slump serves as a poignant reminder of the intricate interplay between policy interventions and market dynamics. The company's CEO's optimistic outlook on the long-term prospects, albeit tempered by immediate financial challenges, underscores the complexity of navigating competing interests. Meanwhile, Eli Lilly's outperformance provides an intriguing counterpoint, illustrating how product efficacy can influence market outcomes. 